Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2013

View Archived Issues

Elan profiles PLK-2 inhibitor ELN-582646 for the treatment of Parkinson's disease

Scientists discover novel small-molecule inhibitor of drug-resistant tuberculosis

Uncovering an amygdala-based mechanism and a potential drug target of PTSD

Auspex commences First-HD phase III trial of SD-809 in Huntington's disease

Omni Bio to provide funding for clinical trial of alpha-1-antitrypsin in GVHD

Hisamitsu Pharmaceutical begins phase II study of HP-3060

Vernalis begins phase Ib/II study of V-81444

Daiichi Sankyo reports results from phase III study of antiplatelet agent in Japan

Nymox reports data from pivotal trial of NX-1207

Namisol shows efficacy in treatment of spasticity and pain in MS

RXi Pharmaceuticals reports findings from second phase I study of RXI-109

Lilly reports promising result for LY-2409021 in patients with type 1 and 2 diabetes

Allergan patents novel prostanoid receptor antagonists

Millennium Pharmaceuticals divulges PI3K type 3 inhibitors

Tissue transglutaminase inhibitors emerge from Sanofi R&D

Alios BioPharma patent describes agents for RSV and influenza

CSIR researchers develop agents for tuberculosis

COPD withdrawn from Japanese NDA for fluticasone furoate/vilanterol

Diazepam nasal spray shows safety and bioavailability comparable to marketed rectal gel formulation

Ipsen and Harvard to collaborate on novel engineered botulinum toxins

FDA approves Gilotrif along with companion diagnostic for first-line treatment of metastatic NSCLC

FDA and EMA issue decisions regarding C-Path's trial simulation tool for Alzheimer's disease

Promising first data for AbbVie compound in mild to moderate Alzheimer's disease

PI3Kbeta inhibitors revealed in GlaxoSmithKline patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...